| Code | CSB-MP006254HU(F1) |
| Abbreviation | Recombinant Human CXCR4 protein-VLPs (Active) |
| MSDS | |
| Size | $558 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
CXCR4 is a seven-transmembrane GPCR central to cancer metastasis, HIV entry, and CXCL12-mediated signaling, yet producing it in a conformationally relevant format presents a well-known technical challenge. This full-length human CXCR4 (aa 1–352) is presented on virus-like particles derived from mammalian cells, preserving the native lipid-bilayer context and post-translational modifications essential for proper GPCR folding and epitope accessibility. Functional ELISA confirms binding activity against an anti-CXCR4 recombinant antibody with an EC50 of 101.7–253.6 ng/mL, providing validated support for ligand-receptor interaction assays, competitive inhibition studies, blocking antibody screening, and therapeutic antibody epitope mapping. Endotoxin levels below 1.0 EU/μg, combined with the membrane-embedded presentation format, satisfy criteria typical for drug discovery workflows involving small-molecule or biologic inhibitor screening and align with standards expected in SPR- or BLI-based affinity characterization where conformational integrity is critical.
Applications : Drug related studies
Review: Currently, CXCR4 has been detected in 23 different types of tumors and is the most commonly expressed chemokine receptor in tumor cells. It is one of the hot targets of drug research and also one of the key targets of our research. After comparing CXCR4 products from multiple manufacturers, we found that CUSABIO\'s CXCR4 product is stable and has good activity. In our ELISA experiment, the EC50 was measured to be 41.51-79.15 ng/ml, which can be used for subsequent research.
By Anonymous